"Sezary Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of cutaneous T-cell lymphoma manifested by generalized exfoliative ERYTHRODERMA; PRURITUS; peripheral lymphadenopathy, and abnormal hyperchromatic mononuclear (cerebriform) cells in the skin, LYMPH NODES, and peripheral blood (Sezary cells).
| Descriptor ID |
D012751
|
| MeSH Number(s) |
C04.557.386.480.750.800.775 C15.604.515.569.480.750.800.775 C15.604.515.841 C20.683.515.761.480.750.800.775 C20.683.515.920
|
| Concept/Terms |
Sezary Syndrome- Sezary Syndrome
- Syndrome, Sezary
- Sezary's Lymphoma
- Lymphoma, Sezary's
- Sezary Lymphoma
- Sezarys Lymphoma
- Erythroderma, Sezary
- Sezary Erythroderma
|
Below are MeSH descriptors whose meaning is more general than "Sezary Syndrome".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, T-Cell [C04.557.386.480.750]
- Lymphoma, T-Cell, Cutaneous [C04.557.386.480.750.800]
- Sezary Syndrome [C04.557.386.480.750.800.775]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, T-Cell [C15.604.515.569.480.750]
- Lymphoma, T-Cell, Cutaneous [C15.604.515.569.480.750.800]
- Sezary Syndrome [C15.604.515.569.480.750.800.775]
- Sezary Syndrome [C15.604.515.841]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, T-Cell [C20.683.515.761.480.750]
- Lymphoma, T-Cell, Cutaneous [C20.683.515.761.480.750.800]
- Sezary Syndrome [C20.683.515.761.480.750.800.775]
- Sezary Syndrome [C20.683.515.920]
Below are MeSH descriptors whose meaning is more specific than "Sezary Syndrome".
This graph shows the total number of publications written about "Sezary Syndrome" by people in this website by year, and whether "Sezary Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 2 | 0 | 2 |
| 2008 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sezary Syndrome" by people in Profiles.
-
ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and S?zary Syndrome. Transplant Cell Ther. 2024 Nov; 30(11):1047-1060.
-
On the Way to Curing Advanced-Stage Mycosis Fungoides/S?zary Syndrome. Clin Lymphoma Myeloma Leuk. 2024 Dec; 24(12):827-836.
-
New JAK3-INSL3 Fusion Transcript-An Oncogenic Event in Cutaneous T-Cell Lymphoma. Cells. 2023 09 29; 12(19).
-
Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory s?zary syndrome. Invest New Drugs. 2023 04; 41(2):350-355.
-
Unmasking a masquerader: Mycosis fungoides unveiled after dupilumab treatment. J Am Acad Dermatol. 2023 06; 88(6):e305-e306.
-
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood. 2022 08 04; 140(5):419-437.
-
Mogamulizumab for Previously Treated Mycosis Fungoides and S?zary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2022 05; 40(5):509-518.
-
Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial. Leuk Lymphoma. 2021 12; 62(13):3109-3118.
-
Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis. Am J Hematol. 2021 09 01; 96(9):E350-E353.
-
Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 02; 21(2):97-105.